title: Daily Intake of Trehalose Is Effective in the Prevention of Lifestyle-Related Diseases in Individuals with Risk Factors for Metabolic Syndrome.
abstract: We previously performed animal studies that suggested that trehalose potentially prevents the development of metabolic syndrome in humans. To evaluate this possibility, we examined whether trehalose suppressed the progression of insulin resistance in a placebo-controlled, double-blind trial in 34 subjects with a body mass index (BMI) ≥23. The subjects were divided into two groups and were assigned to ingest either 10 g/d of trehalose or sucrose with meals for 12 wk. During the study, body composition and blood biochemical parameters were measured at week 0, 8, and 12. These parameters were also measured 4 wk after the end of intake to confirm the washout of test substances. In the trehalose group, blood glucose concentrations after a 2-h oral glucose tolerance test significantly decreased following 12 wk of intake in comparison with baseline values (0 wk). When a stratified analysis was performed in the subjects whose percentage of truncal fat approached the high end of the normal range, the change in body weight, waist circumference, and systolic blood pressure were significantly lower in the trehalose group than in the sucrose group. Our data indicated that a daily intake of 10 g of trehalose improved glucose tolerance and progress to insulin resistance. Furthermore, these results suggested that trehalose can potentially reduce the development of metabolic syndrome and associated lifestyle-related diseases, such as type 2 diabetes.
authors.affiliation: Hayashibara Co. Ltd.
authors.forename: Akiko
authors.initials: A
authors.lastname: Mizote
authors.forename: Mika
authors.initials: M
authors.lastname: Yamada
authors.forename: Chiyo
authors.initials: C
authors.lastname: Yoshizane
authors.forename: Norie
authors.initials: N
authors.lastname: Arai
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Maruta
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Arai
authors.forename: Shin
authors.initials: S
authors.lastname: Endo
authors.forename: Rieko
authors.initials: R
authors.lastname: Ogawa
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Mitsuzumi
authors.forename: Toshio
authors.initials: T
authors.lastname: Ariyasu
authors.forename: Shigeharu
authors.initials: S
authors.lastname: Fukuda
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D001823:Body Composition; D015992:Body Mass Index; D001835:Body Weight; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008019:Life Style; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000188:drug therapy / Q000517:prevention & control*; D008875:Middle Aged; D012307:Risk Factors; D014199:Trehalose / Q000008:administration & dosage* / Q000097:blood; D055105:Waist Circumference
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007328:Insulin; D014199:Trehalose